0.8446
前日終値:
$0.8907
開ける:
$0.8971
24時間の取引高:
322.09K
Relative Volume:
1.28
時価総額:
$37.20M
収益:
$19.94M
当期純損益:
$-37.37M
株価収益率:
-0.8121
EPS:
-1.04
ネットキャッシュフロー:
$-33.38M
1週間 パフォーマンス:
+1.78%
1か月 パフォーマンス:
-18.00%
6か月 パフォーマンス:
-71.47%
1年 パフォーマンス:
-87.49%
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
名前
Werewolf Therapeutics Inc
セクター
電話
617-952-0555
住所
200 TALCOTT AVENUE, WATERTOWN
HOWL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
HOWL
Werewolf Therapeutics Inc
|
0.8446 | 37.20M | 19.94M | -37.37M | -33.38M | -1.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-04-03 | 開始されました | JMP Securities | Mkt Outperform |
2023-08-24 | 開始されました | Wedbush | Outperform |
2023-06-06 | 再開されました | Jefferies | Buy |
2021-09-10 | 開始されました | BofA Securities | Buy |
2021-05-25 | 開始されました | Evercore ISI | Outperform |
2021-05-25 | 開始されました | H.C. Wainwright | Buy |
2021-05-25 | 開始されました | Jefferies | Buy |
2021-05-25 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Werewolf Therapeutics Inc (HOWL) 最新ニュース
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline - Yahoo Finance
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Friday - Defense World
Werewolf Therapeutics stock maintains $4 target, Market Outperform By Investing.com - Investing.com India
Werewolf Therapeutics stock maintains $4 target, Market Outperform - Investing.com
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - GlobeNewswire
Cancer Drug Developer Werewolf Therapeutics Strengthens Leadership Team Amid Promising Clinical Results - Stock Titan
Werewolf Therapeutics names Steven Bloom as CBO - The Pharma Letter
Werewolf Therapeutics stock hits 52-week low at $0.85 - Investing.com Australia
Werewolf Therapeutics stock hits 52-week low at $0.85 By Investing.com - Investing.com South Africa
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Werewolf Therapeutics Reveals Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan
Bank of New York Mellon Corp Grows Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics stock hits 52-week low at $1.02 By Investing.com - Investing.com Australia
Werewolf Therapeutics stock hits 52-week low at $1.02 - Investing.com India
Werewolf Therapeutics Reports 2024 Financial Results and Progress - TipRanks
HC Wainwright Issues Pessimistic Outlook for HOWL Earnings - Defense World
Wedbush Research Analysts Cut Earnings Estimates for HOWL - Defense World
HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Wedbush Reaffirms Outperform Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China - TipRanks
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Inc. (HOWL) reports earnings - Quartz
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c) - TipRanks
Werewolf Therapeutics, Inc. SEC 10-K Report - TradingView
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bakersfield.com
HOWLWerewolf Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference - GlobeNewswire
What Will Werewolf Therapeutics Reveal at the Leerink Biopharma Conference Next Month? - StockTitan
Werewolf Therapeutics, Inc. Announces Board Changes and Committee Appointment - Marketscreener.com
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Werewolf Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock hits 52-week low at $1.25 - Investing.com
Werewolf Therapeutics Announces Board Resignation and New Appointment - Defense World
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors - GlobeNewswire
Werewolf Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Werewolf Therapeutics appoints new board member - Investing.com India
Can This Oncology Pioneer Transform Werewolf's Cancer-Fighting Platform? - StockTitan
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World
Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat
Werewolf Therapeutics Inc (HOWL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):